{
    "clinical_study": {
        "@rank": "112559", 
        "biospec_descr": {
            "textblock": "Eligibility criteria Patients who will use DanshenDuofensuanyan injection in selected\n      hospitals."
        }, 
        "biospec_retention": "None Retained", 
        "brief_summary": {
            "textblock": "This study was advocated by Institute of Basic Research in Clinical Medicine, China Academy\n      of Chinese Medical Sciences in January 2013.\n\n      It was funded by China major scientific and technological specialized project for\n      'significant new formulation of new drugs'.\n\n      DanshenDuofensuanyan is kind of Chinese Medicine injection used for treating coronary heart\n      disease and angina pectoris in many Chinese hospitals.\n\n      The purpose of this study is to determine adverse drug events or adverse drug reaction in\n      large sample size 30,000 patients."
        }, 
        "brief_title": "Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Heart Disease", 
            "Angina Pectoris"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is very common that Chinese Medicine Injection used in hospitals in mainland China.\n      However safety problems rose in recent years. There could be many uncertain factors\n      influence Chinese Medicine Injection in clinical practice.\n\n      In order to ensure the safety of public drug use and lower drug-induced risks, a registry\n      study for DanshenDuofensuanyan injection safety surveillance with 30000 patients will be\n      conducted from Jan.2013 to Dec.2015.\n\n      Eligibility criteria Patients who will use DanshenDuofensuanyan injection in selected\n      hospitals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients using DanshenDuofensuanyan injection from 2013 to 2014\n\n        Exclusion Criteria:\n\n          -  none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "An anticipated sample size was caculated in this study, about 30000 Patients using\n        DanshenDuofensuanyan injection from 2013 to 2014 in more than 20 hospitals"
            }
        }, 
        "enrollment": {
            "#text": "30000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814566", 
            "org_study_id": "2009ZX09502-030-02"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2013", 
        "number_of_groups": "1", 
        "official_title": "Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China", 
        "overall_official": {
            "affiliation": "Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences", 
            "last_name": "Yan M Xie, BA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All patients will be measured and assessed at the time DanshenDuofensuanyan is administered to them until they discharge. Patients using DanshenDuofensuanyan will be registered on a registration form including disease background, DanshenDuofensuanyan's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of DanshenDuofensuanyan.", 
            "measure": "Number of participants with adverse events; incidence of  DanshenDuofensuanyan'adverse drug reaction\uff08ADRs\uff09and identify factors that contributed to the occurrence of the adverse reaction", 
            "safety_issue": "Yes", 
            "time_frame": "to assess DanshenDuofensuanyan's 'adverse event' and 'drug adverse reaction' during patients' hospital stay. The registry procedure will last 2 years only for patients using DanshenDuofensuanyan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814566"
        }, 
        "responsible_party": {
            "investigator_affiliation": "China  Academy of Chinese Medical Sciences", 
            "investigator_full_name": "Yanming Xie", 
            "investigator_title": "Deputy Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "China  Academy of Chinese Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "China  Academy of Chinese Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "14 Days", 
        "verification_date": "March 2013"
    }
}